PL2352497T3 - Proces przygotowania estrów aminokwasowych delta-9-thc - Google Patents

Proces przygotowania estrów aminokwasowych delta-9-thc

Info

Publication number
PL2352497T3
PL2352497T3 PL09824226T PL09824226T PL2352497T3 PL 2352497 T3 PL2352497 T3 PL 2352497T3 PL 09824226 T PL09824226 T PL 09824226T PL 09824226 T PL09824226 T PL 09824226T PL 2352497 T3 PL2352497 T3 PL 2352497T3
Authority
PL
Poland
Prior art keywords
thc
delta
preparation
amino acid
acid esters
Prior art date
Application number
PL09824226T
Other languages
English (en)
Polish (pl)
Inventor
Mahmoud A. Elsohly
Waseem Gul
Michael A. Repka
Soumyajit Majumdar
Original Assignee
University Of Mississippi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Mississippi filed Critical University Of Mississippi
Publication of PL2352497T3 publication Critical patent/PL2352497T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B08CLEANING
    • B08BCLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B13/00Accessories or details of general applicability for machines or apparatus for cleaning
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B08CLEANING
    • B08BCLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B3/00Cleaning by methods involving the use or presence of liquid or steam
    • B08B3/02Cleaning by the force of jets or sprays
    • B08B3/026Cleaning by making use of hand-held spray guns; Fluid preparations therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B08CLEANING
    • B08BCLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B2203/00Details of cleaning machines or methods involving the use or presence of liquid or steam
    • B08B2203/02Details of machines or methods for cleaning by the force of jets or sprays
    • B08B2203/0264Splash guards

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
PL09824226T 2008-10-31 2009-11-02 Proces przygotowania estrów aminokwasowych delta-9-thc PL2352497T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11016508P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
PL2352497T3 true PL2352497T3 (pl) 2017-08-31

Family

ID=42129588

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09824226T PL2352497T3 (pl) 2008-10-31 2009-11-02 Proces przygotowania estrów aminokwasowych delta-9-thc

Country Status (10)

Country Link
US (2) US8809261B2 (enExample)
EP (1) EP2352497B1 (enExample)
JP (1) JP5739344B2 (enExample)
AU (1) AU2009308665B2 (enExample)
CA (1) CA2741862C (enExample)
DK (1) DK2352497T3 (enExample)
ES (1) ES2622582T3 (enExample)
HU (1) HUE032158T2 (enExample)
PL (1) PL2352497T3 (enExample)
WO (1) WO2010051541A2 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160345631A1 (en) 2005-07-19 2016-12-01 James Monsees Portable devices for generating an inhalable vapor
US8991402B2 (en) 2007-12-18 2015-03-31 Pax Labs, Inc. Aerosol devices and methods for inhaling a substance and uses thereof
CA2741862C (en) * 2008-10-31 2017-10-17 Mahmoud A. Elsohly Compositions containing delta-9-thc-amino acid esters and process of preparation
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
US10517530B2 (en) 2012-08-28 2019-12-31 Juul Labs, Inc. Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances
CA2997744C (en) 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CA3142049C (en) 2012-09-12 2023-08-29 Novaliq Gmbh Semifluorinated alkane compositions
US10653180B2 (en) 2013-06-14 2020-05-19 Juul Labs, Inc. Multiple heating elements with separate vaporizable materials in an electric vaporization device
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
ES2999088T3 (en) 2013-05-06 2025-02-24 Juul Labs Inc Nicotine salt formulations for aerosol devices and methods thereof
IL295735B2 (en) 2013-12-05 2024-04-01 Juul Labs Inc Nicotine liquid formulations for aerosol devices and methods thereof
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
PL3504991T3 (pl) 2013-12-23 2021-08-16 Juul Labs International Inc. Systemy urządzeń do odparowywania
CA2948851A1 (en) 2014-05-16 2015-11-19 Pax Labs, Inc. Systems and methods for aerosolizing a smokeable material
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EP4464356A3 (en) 2014-12-05 2025-01-08 Juul Labs, Inc. Calibrated dose control
EP3270896A4 (en) * 2015-03-19 2018-09-12 One World Cannabis Ltd. Preparations of cannabis emulsions and methods thereof
CN105037180B (zh) * 2015-04-19 2017-10-10 安徽省逸欣铭医药科技有限公司 一种双重作用的中枢性镇痛新化合物、制备方法及用途
EP3297617A4 (en) * 2015-05-18 2019-02-20 5071, Inc. HOMOGENEOUS CANNABIC COMPOSITION AND METHOD FOR THE MANUFACTURE THEREOF
CA3176674A1 (en) 2015-05-18 2016-11-24 5071, Inc. Homogenous cannabis compositions and methods of making the same
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
DK3356313T3 (da) 2015-09-30 2020-07-20 Novaliq Gmbh 2-perfluorhexyloktan til oftalmisk indgivelse
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
AU2017212651B2 (en) 2016-01-29 2020-01-23 University Of Mississippi Biologically active cannabidiol analogs
EA039727B1 (ru) 2016-02-11 2022-03-04 Джуул Лэбз, Инк. Надежно прикрепляющиеся картриджи для испарительных устройств
DE202017007467U1 (de) 2016-02-11 2021-12-08 Juul Labs, Inc. Befüllbare Verdampferkartusche
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
CA3021095A1 (en) * 2016-04-15 2017-10-19 Sre Wellness Inc. Method of making cannabis oil hydrophiilic using emulsifiers and related cannabinoid compositions
EP3442521A4 (en) 2016-04-15 2020-01-01 SRE Wellness, Inc. SWEETENERS AND ELIXIRS INFused WITH CANNABIS
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
CA3027913A1 (en) * 2016-06-16 2017-12-21 Teewinot Technologies Limited Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
US11660403B2 (en) 2016-09-22 2023-05-30 Juul Labs, Inc. Leak-resistant vaporizer device
CN109906085B (zh) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 含有环孢素的眼用组合物
CA3036313A1 (en) 2016-09-28 2018-04-05 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
US11117852B2 (en) 2017-04-05 2021-09-14 University Of Mississippi Isolation of pure cannabinoids from Cannabis
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
EP3424494A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
EP3424493A1 (en) 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
US20190015383A1 (en) * 2017-07-14 2019-01-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
IL272601B2 (en) * 2017-08-27 2025-03-01 Rhodes Tech Inc Pharmaceutical compositions for the treatment of ophthalmic conditions
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
SG11202002640YA (en) 2017-09-27 2020-04-29 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
US11498018B2 (en) * 2017-11-27 2022-11-15 Vasilios (Bill) Panagiotakopoulos Extraction and purification of cannabinoid compounds
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
MY206642A (en) 2018-10-12 2024-12-30 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US20220000774A1 (en) * 2018-11-07 2022-01-06 Columbia Care Llc Suppository formulations having cannabinoid
CA3128400A1 (en) * 2019-02-11 2020-08-20 John R. Chancey Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disaccharide, or monosaccharide
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
EP3938359A4 (en) * 2019-03-12 2023-09-27 6th Wave Innovations Corp. MOLECULAR EMBOSSED POLYMERS FOR EXTRACTION OF CANNABINOIDS AND USES THEREOF
CA3136607A1 (en) * 2019-04-09 2020-10-15 Powderpost, Inc. Methods and compositions for use in treatment of cancer without psychoactive effects
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
CN115867533B (zh) 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
CN116685312A (zh) * 2020-11-06 2023-09-01 泽利拉治疗手术私人有限公司 大麻素封装技术
US11242330B1 (en) 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Organic catalyst and method for preparation of aromatic tricyclic pyrans
US11242328B1 (en) 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans
US11352337B1 (en) * 2021-06-02 2022-06-07 Acid Neutral Alkaline Laboratory Zeolite catalyst and method for preparation of aromatic tricyclic pyrans

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB313977A (en) * 1927-12-21 1929-06-21 British United Shoe Machinery Improvements in or relating to boot or shoe sewing machines or methods of making boots or shoes by the use thereof
JPS5518709B2 (enExample) 1970-02-13 1980-05-21
US4933363A (en) * 1988-08-16 1990-06-12 Elsohly Mahmoud A Method for effecting systemic delivery of delta-9-tetrahydrocannabinol
US6040298A (en) * 1992-12-23 2000-03-21 Oclassen Pharmaceuticals, Inc. Methods for treatment with compositions effective against acyclovir-resistant strains of herpes viruses
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
US6008383A (en) * 1998-10-26 1999-12-28 University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol esters
US20060078955A1 (en) * 2004-10-13 2006-04-13 Lin-Zhi International Method for retrieving delta9-THC from oral fluid
WO2006050421A1 (en) 2004-11-02 2006-05-11 New River Pharmaceuticals Inc. Prodrugs of ribavirin with improved hepatic delivery
CA2659775A1 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008134668A2 (en) * 2007-04-27 2008-11-06 Alexza Pharmaceuticals, Inc. Heat-labile prodrugs
CA2990445C (en) * 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US20100303883A1 (en) * 2007-10-17 2010-12-02 Axxia Pharmaceuticals, Llc Polymeric drug delivery systems and thermoplastic extrusion processes for producing such systems
SI2215071T1 (sl) 2007-11-30 2015-12-31 Zynerba Pharmaceuticals, Inc. Predzdravila tetrahidrokanabinola, sestavki, ki obsegajo predzdravila tetrahidrokanabinola in postopki njihove uporabe
US20090169629A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Micellar compositions with ophthalmic applications
EP2151234A1 (en) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
CA2741862C (en) * 2008-10-31 2017-10-17 Mahmoud A. Elsohly Compositions containing delta-9-thc-amino acid esters and process of preparation

Also Published As

Publication number Publication date
WO2010051541A2 (en) 2010-05-06
EP2352497A4 (en) 2012-08-01
US8809261B2 (en) 2014-08-19
ES2622582T3 (es) 2017-07-06
US9630941B2 (en) 2017-04-25
JP2012507568A (ja) 2012-03-29
AU2009308665B2 (en) 2015-10-22
WO2010051541A3 (en) 2010-07-08
AU2009308665A1 (en) 2010-05-06
CA2741862C (en) 2017-10-17
US20150045282A1 (en) 2015-02-12
CA2741862A1 (en) 2010-05-06
JP5739344B2 (ja) 2015-06-24
EP2352497A2 (en) 2011-08-10
US20110275555A1 (en) 2011-11-10
DK2352497T3 (en) 2017-04-03
EP2352497B1 (en) 2017-02-22
HK1158517A1 (en) 2012-07-20
HUE032158T2 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
PL2352497T3 (pl) Proces przygotowania estrów aminokwasowych delta-9-thc
EP2248906A4 (en) PROCESS FOR THE PREPARATION OF L-AMINO ACID
ZA201005436B (en) Process for preparation of high purity methacrylic acid
EP2444389A4 (en) PROCESS FOR THE PREPARATION OF 2-FLUOROACRYLIC ESTERS
PH12012500561A1 (en) Production of fatty acid derivatives
EP2417246A4 (en) PRODUCTION OF FATTY ACID DERIVATIVES
IL206664A0 (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
ZA201109362B (en) Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
ZA201202629B (en) Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
ZA201203615B (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
PL2387558T3 (pl) Sposób wytwarzania i rozdzielania kwasu 2-acyloamino-3-difenylopropanowego
ZA201100528B (en) Method for the synthesis of bioresourced acrylic acid esters
ZA201200160B (en) Process for preparation of (fluoroalkylthio)acetic acid esters
IL220211A0 (en) Process for the preparation of 1-alkyl-/1-aryl-5-pyrazolecarboxylic acid derivatives
PL2240477T3 (pl) Nowy sposób wytwarzania estrów skopiny
IL217001A0 (en) Preparation of substituted 2-fluoroacrylic acid derivatives
IL233132A (en) Process for Preparation of Esters of 5-Fluoro-2-Methyl-3-Quinoline-2-Illmethylindole-1-Ill-Acetic Acid
PT2358851E (pt) Utilização de ácido metanossulfónico para a preparação de ésteres de ácidos gordos
IL219832A0 (en) Process for preparation of (z)-cyanoalkenylcyclopropanecarboxylic acid compounds
IL215870A0 (en) Processes for purification of 1-methylpyrzole-4-carboxylic acid esters
EP2154232A4 (en) PROCESS FOR THE PRODUCTION OF FATTY ACID ESTERS
IL201584A0 (en) Process for the preparation of pure acrylate esters
ZA201107378B (en) Process for the preparation of a biphenyl-2ylcarbamic acid ester
PL2398779T3 (pl) Nowy sposób wytwarzania kwasu nitroorotowego
PL389421A1 (pl) Sposób otrzymywania estrów chityny